viDA Therapeutics, Inc. (viDA), is advancing first-in-class drugs based on inhibitors of the extracellular serine protease, Granzyme B (GzmB), to treat autoimmune and chronic inflammatory diseases.  The company is focused on advancing their lead candidate into the clinic for the treatment of the orphan disease, Discoid Lupus Erythematosus (DLE), a chronic inflammatory autoimmune skin disorder. Based on preclinical studies with our topically formulated lead compound VTI-1002, the company is planning to file an Investigational New Drug (IND) application with the FDA within the next 12 months.



Dr. David Granville, viDA CSO, to Present at Society for
Leukocyte Biology 50th Annual Meeting

viDA Therapeutics 2017 Corporate Presentation

Granville Laboratory Receives Inaugural Michael Smith Foundation
for Health Research Innovation to Commercialization (I2C) Award

viDA Therapeutics Inc. Appoints Orphan Product Regulatory
Executive Dr. Marlene Haffner to Board of Directors